OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
May 25, 2024
In an ASGCT Panel on nucleic acid- and cell-based vaccines in oncology, work on a personalized mRNA vaccine was highlighted.
The partnership aims to provide end-to-end development and manufacturing for biopharmaceutical drug substance and drug product.
May 24, 2024
With the acquisition, Biogen gains felzartamab, HI-Bio's lead investigational mAb candidate being developed for the treatment of a range of immune-mediated diseases.
May 21, 2024
Webinar Date/Time: Mon, Jun 24, 2024 11:00 AM EDT
May 20, 2024
The new facility will be the company’s first to offer full manufacturing processing for antibody drug conjugates.
May 18, 2024
Bari Kowal, senior vice-president, head Development Operations & Portfolio Management, Regeneron, discussed the utility of AI and how it can benefit R&D work.
May 17, 2024
Ken Keller, president and CEO, Daiichi Sankyo, discusses the foundation of partnership and takes a look at the future of biotech partnerships at the US Pharma and Biotech Summit.
May 16, 2024
Webinar Date/Time: Wednesday, May 29th 11am EDT | 4pm GMT | 5pm CEST
Webinar Date/Time: Wed, Jun 12, 2024 11:00 AM EDT
May 11, 2024
Regeneron's Sven Moller-Tank, PhD, director of Viral Delivery Technologies, Regeneron Genetic Medicines, discusses the company's work in using bispecific antibodies for redirecting AAV target specificity.